'Selective' COX-1 or COX-2 NSAIDs: Time to change a misleading measure

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 5, 2014, Pages 455-456

  Raffa, R B ^a   Gudin, J A ^b   Nalamachu, S ^c   Pergolizzi, J V ^d,e,f  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^c Clinical Research   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN H; PROSTAGLANDIN SYNTHASE; THROMBOXANE; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR;

DRUG BLOOD LEVEL; EDITORIAL; IC 50; PUBLICATION; STEADY STATE; EPIDEMIOLOGY; HUMAN; IC50; METABOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFOUNDING FACTORS (EPIDEMIOLOGY); CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50;

EID: 84906939834     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12192     Document Type: Editorial

References (7)

1. Vane JR, Botting RM,. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med, 1998; 104 (Suppl 1): 2S-8S.
2. Flower RJ,. Case history: the development of COX-2 inhibitors. Nat Rev Drug Discov, 2003; 2: 179-191.
3. Warner TD, Giuliano F, Vojnovic I, et al,. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A, 1999; 96: 7563-7568.
4. Blain H, Boileau C, Lapicque F, et al,. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Brit J Clin Pharmacol, 2002; 53: 255-265.
5. Waterbury LD, Silliman D, Jolas T,. Comparison of cyclooxygenase inhibitory activity and ocular ant-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin, 2006; 22: 1133-1140.
6. Knights KM, Mangoni AA, Miners JO,. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Exp Rev Clin Pharmacol, 2010; 3: 769-776.
7. Vitale P, Tacconelli S, Perrone MG, et al,. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. J Med Chem, 2013; 56: 4277-4299.